Wenjin Yang
Chief Tech/Sci/R&D Officer bei FORESEE PHARMACEUTICALS CO., LTD.
Profil
Wenjin Yang was the founder of Aldea Pharmaceuticals, Inc. founded in 2011, where he held the title of Officer from 2011 to 2014.
He is currently the Chief Scientific Officer at Foresee Pharmaceuticals Co., Ltd.
since 2015.
Dr. Yang's former positions include Director & Head-Medicinal Chemistry at Sunesis Pharmaceuticals, Inc., Principal at Gilead Sciences, Inc., Vice President-Chemistry at Eiger BioPharmaceuticals, Inc., and Associate at The Scripps Research Institute.
Dr. Yang's education includes a graduate and doctorate degree from the University of California, Berkeley, an undergraduate and doctorate degree from National Taiwan University, and an undergraduate degree from Chinese Culture University.
Aktive Positionen von Wenjin Yang
| Unternehmen | Position | Beginn |
|---|---|---|
| FORESEE PHARMACEUTICALS CO., LTD. | Chief Tech/Sci/R&D Officer | 21.09.2015 |
Ehemalige bekannte Positionen von Wenjin Yang
| Unternehmen | Position | Ende |
|---|---|---|
Aldea Pharmaceuticals, Inc.
 Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA. | Founder | - |
The Scripps Research Institute
 The Scripps Research Institute Other Consumer ServicesConsumer Services The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California. | Corporate Officer/Principal | - |
| VIRACTA THERAPEUTICS, INC. | Director/Board Member | - |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | - |
Eiger BioPharmaceuticals, Inc. /Old/
 Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Corporate Officer/Principal | - |
Ausbildung von Wenjin Yang
| University of California, Berkeley | Doctorate Degree |
| National Taiwan University | Doctorate Degree |
| Chinese Culture University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| FORESEE PHARMACEUTICALS CO., LTD. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Eiger BioPharmaceuticals, Inc. /Old/
Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Health Technology |
Aldea Pharmaceuticals, Inc.
Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA. | Health Technology |
